48 related articles for article (PubMed ID: 31245212)
1. Influence of
Thomas L; Raju AP; Chaithra S; Kulavalli S; Varma M; Sv CS; Baneerjee M; Saravu K; Mallayasamy S; Rao M
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):263-274. PubMed ID: 38287694
[TBL] [Abstract][Full Text] [Related]
2. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil.
Ridolfi F; Amorim G; Peetluk LS; Haas DW; Staats C; Araújo-Pereira M; Cordeiro-Santos M; Kritski AL; Figueiredo MC; Andrade BB; Rolla VC; Sterling TR;
J Infect Dis; 2024 Mar; 229(3):813-823. PubMed ID: 38262629
[TBL] [Abstract][Full Text] [Related]
3. A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.
Verma R; da Silva KE; Rockwood N; Wasmann RE; Yende N; Song T; Kim E; Denti P; Wilkinson RJ; Andrews JR
medRxiv; 2023 Sep; ():. PubMed ID: 37732197
[TBL] [Abstract][Full Text] [Related]
4. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
5. Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population.
Yadav D; Kumar R; Dixit RK; Kant S; Verma A; Srivastava K; Singh SK; Singh S
Cureus; 2019 Apr; 11(4):e4425. PubMed ID: 31245212
[TBL] [Abstract][Full Text] [Related]
6.
Mohamed Noor NF; Salleh MZ; Mohd Zim MA; Bakar ZA; Fakhruzzaman Noorizhab MN; Zakaria NI; Lailanor MI; Teh LK
Pharmacogenomics; 2022 Jun; 23(9):531-541. PubMed ID: 35615896
[No Abstract] [Full Text] [Related]
7. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
8. Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients.
Rana SV; Ola RP; Sharma SK; Arora SK; Sinha SK; Pandhi P; Singh K
Hepatol Int; 2012 Jan; 6(1):397-402. PubMed ID: 22020825
[TBL] [Abstract][Full Text] [Related]
9. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
[TBL] [Abstract][Full Text] [Related]
10. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
[TBL] [Abstract][Full Text] [Related]
11. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
Guaoua S; Ratbi I; Laarabi FZ; Elalaoui SC; Jaouad IC; Barkat A; Sefiani A
BMC Genet; 2014 Dec; 15():156. PubMed ID: 25544508
[TBL] [Abstract][Full Text] [Related]
12. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
Ng CS; Hasnat A; Al Maruf A; Ahmed MU; Pirmohamed M; Day CP; Aithal GP; Daly AK
Eur J Clin Pharmacol; 2014 Sep; 70(9):1079-86. PubMed ID: 24888881
[TBL] [Abstract][Full Text] [Related]
13. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients.
Zaverucha-do-Valle C; Monteiro SP; El-Jaick KB; Rosadas LA; Costa MJ; Quintana MS; de Castro L
Tuberculosis (Edinb); 2014 May; 94(3):299-305. PubMed ID: 24793319
[TBL] [Abstract][Full Text] [Related]
14. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
